Blue Again: Perturbational Effects of Antidepressants Suggest Monoaminergic Homeostasis in Major Depression by Andrews, Paul W. et al.
Millions of people are affected by depression each year. 
Approximately 6.6% of adults, or about 13 million of the adult US 
population, are estimated to have had episodes that meet current 
criteria for MDD within a year’s time (Kessler et al., 2007). Based on 
a single interview, the lifetime prevalence of MDD is estimated to be 
16.2%, or 33 million of the adult population (Kessler et al., 2007). 
However, lifetime estimates from single interviews are conservative 
because interviewees vary greatly in their current age and they have 
difficulty recalling prior episodes of depressive symptoms (Wells 
and Horwood, 2004; Kessler et al., 2005; Kruijshaar et al., 2005; 
Moffitt et al., 2009). Longitudinal studies of community samples in 
which participants are repeatedly interviewed yield higher estimates 
of the lifetime prevalence of MDD, often exceeding 40% (Wells 
and Horwood, 2004; Kruijshaar et al., 2005; Moffitt et al., 2009).
Most episodes that meet diagnostic criteria for MDD are asso-
ciated with stressors (e.g., bereavement, marital difficulties, inter-
personal conflict, financial difficulties, health issues). For instance, 
in a longitudinal study of a large community sample of twins of 
both sexes, 88.1% of diagnosed episodes of MDD were associated 
with a stressor of some sort (Keller et al., 2007). Only 11.9% of 
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Depression is an affective state of negative mood and low arousal. 
According to the current text revision version of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV-TR), about 
of depression constitutes an episode of major depressive disor-
der (MDD) if it is denoted by at least five of nine symptoms: (1) 
depressed mood; (2) anhedonia; (3) significant weight loss (or 
gain), or a decrease (or increase) in appetite; (4) insomnia (or 
hypersomnia); (5) psychomotor retardation (or agitation); (6) 
fatigue or loss of energy; (7) feelings of worthlessness or guilt; (8) 
diminished ability to concentrate; and (9) recurrent thoughts of 
death (not just fear of dying), or suicidal thoughts or actions. One 
of the symptoms must be either depressed mood or anhedonia. 
Additionally, the episode must last for at least 2 weeks, and it must 
cause substantial distress or impairment in an important domain of 
functioning. Finally, the episode must not be better accounted for 
by bereavement (which assumes that the episode is not disordered 
if it causes significant impairment for up to 2 months), and must 
not be caused by a substance or a medical condition (American 
Psychiatric Association, 2000).
Blue again: perturbational effects of antidepressants suggest 
monoaminergic homeostasis in major depression
Paul W. Andrews1,2*, Susan G. Kornstein3, Lisa J. Halberstadt1, Charles O. Gardner1 and Michael C. Neale1
1  Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA
2  Department of Psychology, Neuroscience and Behaviour, McMaster University, Hamilton, ON, Canada
3  Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA
Some evolutionary researchers have argued that current diagnostic criteria for major depressive 
disorder (MDD) may not accurately distinguish true instances of disorder from a normal, 
adaptive stress response. According to disorder advocates, neurochemicals like the monoamine 
neurotransmitters (serotonin, norepinephrine, and dopamine) are dysregulated in major 
depression. Monoamines are normally under homeostatic control, so the monoamine disorder 
hypothesis implies a breakdown in homeostatic mechanisms. In contrast, adaptationist 
hypotheses propose that homeostatic mechanisms are properly functioning in most patients 
meeting current criteria for MDD. If the homeostatic mechanisms regulating monoamines are 
functioning properly in these patients, then oppositional tolerance should develop with prolonged 
antidepressant medication (ADM) therapy. Oppositional tolerance refers to the forces that develop 
when a homeostatic mechanism has been subject to prolonged pharmacological perturbation 
that attempt to bring the system back to equilibrium. When pharmacological intervention is 
discontinued, the oppositional forces cause monoamine levels to overshoot their equilibrium 
levels. Since depressive symptoms are under monoaminergic control, this overshoot should 
cause a resurgence of depressive symptoms that is proportional to the perturbational effect 
of the ADM. We test this prediction by conducting a meta-analysis of ADM discontinuation 
studies. We find that the risk of relapse after ADM discontinuation is positively associated with 
the degree to which ADMs enhance serotonin and norepinephrine in prefrontal cortex, after 
controlling for covariates. The results are consistent with oppositional tolerance, and provide 
no evidence of malfunction in the monoaminergic regulatory mechanisms in patients meeting 
current diagnostic criteria for MDD. We discuss the evolutionary and clinical implications of 
our findings.
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an environmental trigger). However, even many of the apparently 
endogenous episodes could have reflected a reluctance to disclose 
stressors of a sensitive nature (Leff et al., 1970).
There are two broadly divergent approaches to the relation-
ship between stressors and depression. In some way, the relation-
ship must be mediated by the brain, but the neurological causes of 
depression are generally acknowledged to be unknown (Berton and 
Nestler, 2006). Many researchers, certain that depressive symptoms 
are maladaptive, search for evidence of stress-induced malfunction 
in the brain (for recent reviews, see Krishnan and Nestler, 2008; 
Savitz and Drevets, 2009). These researchers attempt to identify 
the neurological mechanisms responsible for the chronic nature of 
depression and its association with a variety of medical conditions 
(McEwen, 1998, 2007), the structural changes in the brain associ-
ated with depression and their effects on cognition (Sapolsky, 1996, 
2000, 2001; Duman, 2004; Duman and Monteggia, 2006; Savitz and 
Drevets, 2009), and the neurochemical pathways of depression, 
including the mechanisms by which antidepressant medications 
(ADMs) reduce symptoms (for a review, see Krishnan and Nestler, 
2008). An integrating theme in this research is that the neurochemis-
try of depression is disordered, although the precise neurochemicals 
that are dysregulated are the subject of much debate and research. 
Monoamine neurotransmitters, glucocorticoids, neurotrophins, 
and cytokines are the major chemicals thought to be involved in 
depression (Krishnan and Nestler, 2008). Regardless of the role of 
other chemicals, there seems to be consensus that the monoamine 
neurotransmitters – particularly serotonin (5- hydroxytryptamine 
or 5-HT), norepinephrine (NE), and, to a lesser extent, dopamine 
(DA) – are directly or indirectly involved in the biochemical path-
ways to depression (Krishnan and Nestler, 2008). All ADMs, for 
instance, act on monoamines through a variety of mechanisms 
(see below). Moreover, research on rodents in which monoaminer-
gic receptors have been knocked out, or monoamine transmission 
has been disabled, has provided strong experimental evidence that 
monoamines play a role in depressive symptoms and in the antide-
pressant response, particularly 5-HT and NE (Heisler et al., 1998; 
Mayorga et al., 2001; Cryan et al., 2004; Dziedzicka-Wasylewska 
et al., 2006).
Other researchers argue that depressive symptoms might be bet-
ter described by adaptive mechanisms that respond to stressors and 
threats (Price et al., 1994; Nesse, 2000, 2004; Watson and Andrews, 
2002; Allen and Badcock, 2003, 2006; Hagen, 2003; Gilbert, 2006; 
Horwitz and Wakefield, 2007; Andrews and Thomson Jr., 2009; 
Nesse and Ellsworth, 2009; Price, 2009). These hypotheses do not 
propose that all episodes of depression are adaptive since all evolved 
adaptations in the body are susceptible to malfunction and disor-
der at some rate. Rather, the issue is whether the symptoms cur-
rently used to diagnose depressive disorder accurately distinguish 
the disordered state from normal, adaptive processes (Spitzer and 
Wakefield, 1999; Horwitz and Wakefield, 2007; Wakefield et al., 
2007, 2010). Some adaptationist hypotheses restrict their applica-
tion to symptoms and episodes that do not meet diagnostic thresh-
olds, but such restrictions are intended to exclude true instances 
of disorder. Consequently, these hypotheses are not falsified in 
any rigorous sense by evidence that current diagnostic criteria are 
inaccurate. In any event, evolutionarily oriented researchers tend 
to focus on the ecological mapping of the symptoms of depres-
sion (and the cognitive and behavioral outputs) to the stressors 
that trigger episodes (Gilbert and Allan, 1998; Hagen, 1999, 2002; 
Badcock and Allen, 2003; Gilbert et al., 2004; Keller and Nesse, 
2004, 2005, 2006; Andrews et al., 2007; Wrosch and Miller, 2009), 
largely treating the brain as a black box whose internal structure 
and operation are unknown.
Both approaches agree that the body has evolved adaptations for 
responding to stress. They both believe that, in general, environ-
mental stressors trigger mechanisms in the body that regulate mul-
tiple body systems so that cognition and behavior can be adaptively 
modulated to meet the environmental challenge. They also agree 
that these evolved stress response mechanisms can malfunction. 
They primarily differ in what constitutes evidence of depressive 
disorder and the causes of depressive disorder.
Most articulations of the monoamine disorder hypothesis pro-
pose that forebrain levels of monoamine neurotransmitters are 
depleted in depressive disorder – particularly serotonin (5-HT), 
norepinephrine (NE) and, to a lesser extent, dopamine (DA). 
However, some have suggested that monoaminergic transmission 
may be enhanced in depression (Sapolsky, 2004). The precise direc-
tion of association between depression and forebrain monoamine 
levels is not crucial for the present paper. It is sufficient to say that 
the neurochemical disorder hypothesis proposes that monoamines, 
particularly 5-HT and NA, are perturbed in some way.
But monoaminergic perturbation, per se, is not evidence of dis-
order. The most prominent definition of disorder is based in evo-
lutionary theory (Spitzer, 2007), and it argues that at heart of every 
disorder is an evolved adaptation that is malfunctioning (Wakefield, 
1992). Under this definition, the claim that depression is a disorder 
of too much or too little of a neurotransmitter is ultimately a claim 
that the evolved mechanisms that control neurotransmitter levels 
are malfunctioning.
Monoamine neurotransmitter levels are normally under homeo-
static control (Best et al., 2010). Homeostasis involves the regulation 
of an important substance or physiological parameter within a nar-
row range around an equilibrium. Minimally, homeostatic mecha-
nisms have a sensor for determining how far the parameter deviates 
from the equilibrium and feedback mechanisms for bringing the 
parameter back to equilibrium (Woods, 2009). For instance, the 
homeostatic control of core body temperature involves neuronal 
sensors in the preoptic anterior hypothalamus that connect with 
various efferent pathways to exert feedback and keep temperature 
at equilibrium (Romanovsky, 2007). Additionally, many homeo-
static mechanisms can raise or lower the equilibrium in response 
to environmental contingencies. Thus, the body often responds to 
an infection by raising the core body temperature equilibrium – 
otherwise known as fever (Romanovsky et al., 2005). Feedback 
mechanisms then maintain core body temperature around this 
elevated equilibrium. Because some infections last for weeks or 
months, fever can last for extended periods of time.
If depression is, in whole or in part, a disorder in the homeostatic 
mechanisms that regulate monoamine transmission, then it could 
involve malfunction in: (1) the sensors that monitor monoam-
ine levels (2) the feedback mechanisms that maintain monoam-
ine levels at the equilibrium; or (3) the mechanisms that alter the 
equilibrium point.
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comes from a meta-analysis of studies examining the risk of relapse 
among patients with remitted symptoms after ADM treatment had 
been discontinued (Viguera et al., 1998). The authors found that the 
risk of relapse was positively associated with the duration of ADM 
treatment. While this relationship was not statistically significant, 
it became marginally significant in a re-analysis that included an 
additional study (Baldessarini et al., 2002). Such evidence suggests 
oppositional tolerance because longer treatment periods provide 
homeostatic mechanisms with more time to make neurological 
changes that oppose pharmacological perturbation (Fava and 
Offidani, 2011). However, several subsequent meta-analyses have 
failed to find any evidence that treatment duration affected the 
risk of relapse after discontinuation (Geddes et al., 2003; Kaymaz 
et al., 2008; Glue et al., 2010). At present, evidence of oppositional 
tolerance in depression is equivocal.
Antidepressant medications vary widely in the degree to 
which they perturb monoamine levels in the brain (see below). 
Consequently, perturbational differences in ADMs could affect the 
degree of oppositional tolerance. This is analogous to the negative 
feedback forces that springs exert when they are displaced from 
their equilibrium position. As one pulls a spring from its equilib-
rium position, the spring exerts an oppositional force that attempts 
to bring the spring back to equilibrium; the more further one dis-
places the spring from its equilibrium position, the greater the 
oppositional force that the spring produces. Similarly, ADMs with 
greater perturbational effects should trigger stronger oppositional 
forces that attempt to bring monoamine levels back to equilibrium. 
The buildup of oppositional tolerance under ADM treatment could 
then cause the system to overshoot its equilibrium upon discon-
tinuation, and the degree of overshoot should be proportional to 
the perturbational effect of the ADM.
We hypothesize that monoamine levels are under homeostatic 
control in patients diagnosed with MDD, and that ADM treatment 
will cause oppositional tolerance. There are two implications for the 
present paper. First, the buildup of oppositional tolerance during 
ADM treatment will attempt to bring monoamine levels back to 
equilibrium, which will cause them to overshoot the equilibrium 
after ADM treatment is discontinued. Second, the degree to which 
monoamine levels overshoot the equilibrium will be positively 
related to the perturbational effect of the ADM. We do not directly 
test these implications because we lack relevant perturbational data 
in humans. Rather, we test two predictions that follow from them.
Since depressive symptoms are under monoaminergic control, 
ADM treatment tends to decrease depressive symptoms. However, 
oppositional tolerance during ADM treatment should build pres-
sure for increasing symptoms (Fava and Offidani, 2011). After ADM 
treatment is discontinued, the overshoot of monoamines will cause 
an increase in symptoms that could exceed diagnostic thresholds 
for a relapse or a recurrence of MDD (hereafter, just relapse). Since 
oppositional tolerance will be absent in patients who resolve their 
episodes without ADM treatment, we predict that the risk of relapse 
among patients who discontinue ADM treatment will be higher 
than the risk of relapse among patients who remit without ADM 
treatment. Second, and more importantly, we predict that the risk 
of relapse will be positively related to the perturbational effect of 
the ADM.
Although most adaptationist research treats the brain as a 
black box, a common (if unstated) implication of all adaptation-
ist hypotheses for depression is that the relevant neurochemistry 
is altered to change cognition and behavior in ways that adapt 
the organism to the environmental contingencies that triggered 
the episode. An adaptationist perspective on the chronic nature 
of depression suggests that, like fever, monoamines may be under 
the control of a homeostatic mechanism that maintains forebrain 
levels at an altered equilibrium for an extended period of time, 
presumably because the nature of the stressor requires it (see, e.g., 
Andrews and Thomson Jr., 2009).
The disruption of a mechanism by pharmacological interven-
tion can reveal whether it is under homeostatic control (Young 
and Goudie, 1995). Acute exposure to opiates inhibits the firing 
of noradrenergic neurons in the locus coeruleus by suppressing 
cyclic adenosine 3′,5′-monophosphate (cAMP) levels (Nestler and 
Aghajanian, 1997). However, with long-term (chronic) exposure, 
firing rates return to normal because a negative feedback mecha-
nism upregulates the cAMP pathway so that it counteracts the 
drug’s effect and returns the system to the equilibrium (Nestler 
and Aghajanian, 1997). The neurological changes brought about 
by homeostatic mechanisms that counteract the disrupting effects 
of chronic drug exposure are referred to as oppositional tolerance 
(Young and Goudie, 1995; Fava and Offidani, 2011). These coun-
teractive forces can cause the system to overshoot the equilibrium 
when the drug is abruptly discontinued (Young and Goudie, 1995; 
Fava and Offidani, 2011). Thus, when an opioid receptor antago-
nist is used to abruptly block an opiate, the upregulated cAMP 
pathway causes firing rates to exceed the normal rate (Nestler and 
Aghajanian, 1997).
Some researchers have called for greater research on the neu-
rological responses of homeostatic mechanisms to chronic psy-
chotropic drug use, including ADMs (Hyman and Nestler, 1996). 
Others have specifically hypothesized that oppositional tolerance 
to ADMs may develop in depression (Fava and Offidani, 2011). 
Whether the monoamines thought to cause major depression are 
under homeostatic control has important implications for debates 
about whether most episodes of MDD are instances of a properly 
functioning adaptation or true instances of disorder. Homeostatic 
mechanisms are classic examples of adaptations. Survival and 
reproduction require the internal environment of the organism 
to be regulated (Hochochka and Somero, 2002; Woods, 2009). The 
machinery needed to exert negative feedback to maintain physi-
ological conditions within a narrow band around an equilibrium 
are often complex and difficult to explain by any process other 
than natural selection. Consequently, evidence that monoamine 
neurotransmitters were under homeostatic control in patients 
diagnosed with MDD would suggest that those mechanisms were 
not malfunctioning.
In this paper, we focus on a straightforward implication of the 
hypothesis that depression neurochemistry is under homeostatic 
control: ADM-induced perturbations to monoamine neuro-
transmitter levels should trigger oppositional tolerance. Previous 
research provides some support for oppositional tolerance to ADMs 
in patients diagnosed with MDD. It is not uncommon for depres-
sive symptoms to reemerge after remission while patients are on 
maintenance ADM therapy (Byrne and Rothschild, 1998), which is 
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be important (Drevets, 1998; Andrews and Thomson Jr., 2009), 
which may seem incongruent with the rodent literature. However, 
the rodent brain is organized differently than the human brain, 
and the rodent mPFC is a likely structural and functional 
homolog to the human VLPFC (Uylings and Vaneden, 1990; 
Kesner, 2000; Uylings et al., 2003). The perturbational effects of 
ADMs on rodent mPFC monoamine levels may correspond to 
their perturbational effects in human brain regions implicated 
in depression, such as the VLPFC. Unless otherwise indicated, 
we rely on microdialysis studies in which a single dose in the 
10–15 mg/kg range was systemically administered (either by 
intraperitoneal injection or oral administration). This dose range 
is commonly used and approximates clinically relevant doses 
(Koch et al., 2003). From these studies, we extracted the average 
percent increase of each monoamine (5-HT, NE, and DA) above 
baseline in the mPFC (see Table 1).
Microdialysis studies of mPFC monoamine levels can be 
found for most of the major standalone ADMs used in discon-
tinuation studies. However, we lack mPFC microdialysis data for 
the two monoamine oxidase inhibitors (MAOIs) – phenelzine 
and   selegiline – that have been used in discontinuation studies. 
Phenelzine is a dual MAO-A/B inhibitor, and so is selegiline at the 
doses used in the discontinuation study (Stahl, 2008). As noted 
above, the inhibition of MAO-A primarily increases 5-HT and 
NE. Although MAO-B does not metabolize 5-HT or NE, it does 
metabolize β-phenylethylamine, which is related to the release of 
catecholamines, including 5-HT and NE (Kitaichi et al., 2010). The 
inhibition of MAO-B can therefore indirectly increase 5-HT and 
NE as well as directly increase DA (Kitaichi et al., 2010).
We conduct a meta-analysis to test these predictions. Other 
meta-analyses of ADM discontinuation studies have been con-
ducted (Viguera et al., 1998; Geddes et al., 2003; Kaymaz et al., 
2008; Glue et al., 2010), but they have not been specifically designed 
to address these questions. Moreover, our meta-analysis offers an 
important methodological improvement. ADM discontinuation 
studies vary widely in the criteria that are used to define a relapse. 
Some studies use a threshold score on a single assessment instru-
ment, while others may use a complex combination of different 
instruments assessed over multiple time periods. These definitional 
criteria can have a dramatic affect on the relapse rate (Montgomery 
and Dunbar, 1993; Keller et al., 1998). Studies that use more 
stringent relapse criteria make it more difficult for an increase in 
symptoms to qualify as a relapse, resulting in lower relapse rates 
(Montgomery and Dunbar, 1993). Prior meta-analyses have not 
attempted to control for the variability in the stringency of relapse 
criteria in discontinuation studies, possibly because it is difficult 
to objectively compare relapses defined by different instruments. 
For each study, we construct a variable (called stringency) that can 
be objectively calculated as the number of assessment hurdles that 
have to be passed before an increase in symptoms will be defined as 
a relapse. In general, studies with more assessment hurdles should 
make it more difficult for an increase in symptoms to qualify as a 
relapse. If so, our stringency variable should be a negative predictor 
of the relapse rate.
Before describing the design of our meta-analysis in detail, we 
discuss how the major ADM classes differ in the degree to which 
they perturb monoamine neurotransmitter levels.
PerturbatIonal effects of adMs
Monoaminergic neurons originate in various areas of the midbrain 
and project to forebrain regions. After monoamines are released 
into the synapse, they are eventually taken back into the presynaptic 
neuron by molecules called transporters. Once they are taken back 
inside the cell, monoamines are broken down by two enzymes – 
monoamine oxidase A (MAO-A), which breaks down 5-HT, NE, 
and DA, and monoamine oxidase B (MAO-B), which breaks down 
DA, but not 5-HT or NE.
All ADMs have multiple pharmacological effects by binding to 
various receptors, transporters, and enzymes. This could make it 
difficult to classify them in terms of their perturbational impact. 
However, one relatively clear measure of perturbational impact is 
by whether cortical levels of the monoamine neurotransmitters – 
5-HT, NE, and DA – are actually affected. When cortical levels 
of a neurotransmitter are influenced by an ADM, the drug exerts 
perturbational influence through all the receptors, transporters, 
and enzymes to which the neurotransmitter binds.
The perturbational effects of ADMs on monoamine forebrain 
levels have not been directly measured in humans because it 
requires invasive techniques. However, microdialysis studies 
of rodents have examined the perturbational effects of ADMs 
in various brain regions. Since there is regional variability in 
the effects of ADMs, we look at microdialysis studies assessing 
the in vivo effects of ADMs on rodent medial prefrontal cortex 
(mPFC) monoamine levels. We choose the mPFC because it plays 
an important role in behavioral depression in rodents (Amat 
et al., 2005, 2006, 2010; Baratta et al., 2009). In human depres-
Table 1 | Perturbational effects of antidepressants on mPFC levels of 
monoamine neurotransmitters (expressed as percent over baseline).
ADM  p5HT  pNE  pDA  ADM class  Reference
Phenelzine  400  400  400  MAOI  See text
Selegiline  400  400  400  MAOI  See text
Desvenlafaxine  250  230  167  SNRI  See text
Duloxetine  195  270 200 SNRI  Kihara and Ikeda (1995),   
        Koch et al. (2003)
Milnacipran  94  147 119  SNRI  Marien et al. (2007)
Venlafaxine  250  230 167 SNRI  Koch et al. (2003),  
        Weikop et al. (2007)
Citalopram  466 90 71 SSRI  Bymaster et al. (2002)
Escitalopram  466  90  71  SSRI  See text
Fluoxetine  368  189 150 SSRI  Bymaster et al. (2002)
Fluvoxamine  255  121 102 SSRI  Bymaster et al. (2002)
Paroxetine  364  86  103 SSRI  Bymaster et al. (2002)
Sertraline  438  117 116 SSRI  Bymaster et al. (2002)
Amitriptyline  100  200 175  TCA  Kihara and Ikeda (1995)
Clomipramine 150  200 320 TCA  Koch et al. (2003),  
        Tanda et al. (1994)
Desipramine  100  210 250 TCA  Seo et al. (1999),  
        Tanda et al. (1994)
Imipramine  175  300 200 TCA  Jordan et al. (1994)
Nortriptyline  100  200  175  TCA  See text
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NE transporters, although, as a class, they tend to have greater 
affinity for the NE transporter. We relied on several studies (Jordan 
et al., 1994; Tanda et al., 1994; Kihara and Ikeda, 1995; Koch et al., 
2003; Bongiovanni et al., 2008) to get data on the mPFC mono-
amine effects of the TCAs that have been used in discontinuation 
studies – amitriptyline, clomipramine, desipramine, imipramine, 
and nortriptyline. We lacked microdialysis data for nortriptyline, 
but since it is the active metabolite of amitriptyline, we assigned it 
the same perturbational values.
study overvIew
To summarize, we conduct a meta-analysis to test two predictions 
of the hypothesis that monoamine levels are under homeostatic 
control in patients diagnosed with MDD. First, patients who remit 
with ADM treatment will have a higher risk of relapse after treat-
ment stops than patients who remit without ADM treatment. 
Second, the risk of relapse after ADM treatment is discontinued 
will be positively related to the perturbational effects of the ADM 
on prefrontal monoamine levels.
Two types of studies are relevant to these predictions. In ADM 
extension studies, patients diagnosed with MDD are initially ran-
domly assigned to ADM or placebo during the treatment phase, 
and then remitters in both groups are followed in an extension 
phase in which they continue to receive the same treatment. Since 
our first prediction relates to the risk of relapse after remission 
without ADM treatment, we only consider the Placebo–Placebo 
arms of extension studies. We put placebo in its own class (PBO) 
and assign to placebo treatment a perturbational score of 100 (no 
effect on baseline levels) for each of the monoamines.
In ADM discontinuation studies, all patients diagnosed with 
MDD go through an initial ADM treatment phase and then remit-
ters go through a discontinuation phase in which they are randomly 
assigned, under double-blind conditions, to either continued treat-
ment (Drug–Drug) or placebo (Drug–Placebo). Since our second 
prediction deals with the risk of relapse after ADM discontinua-
tion, we only consider the Drug–Placebo arms of discontinuation 
studies.
In our meta-analysis, we include all the randomized, double-
blind, placebo-controlled ADM extension studies we can find 
since patients in the Placebo–Placebo arms of these studies have 
not received any pharmacological treatment. However, we limit 
analysis to ADM discontinuation studies in which patients receive 
chronic treatment of a single ADM from one of the major stan-
dalone classes – the MAOIs, the TCAs, the SNRIs, or the SSRIs. As 
a practical matter, microdialysis data on the mPFC monoaminergic 
effects of ADMs from outside these classes is limited.
study selectIon
Design of relevant studies
Studies included in our meta-analysis had to meet several design 
criteria. First, patients must have had a primary diagnosis of an 
episode of unipolar major depression (MDD, recurrent or chronic, 
with or without dysthymia). A variety of diagnostic methods were 
allowed. Additionally, most published studies excluded depressed 
patients who had a diagnosis of bipolar disorder or concurrent alco-
hol or substance abuse. We therefore excluded studies specifically 
Of the ADMs, dual MAO-A/B inhibitors exert the most powerful 
effects on monoamine levels. Due to differences in regional effects 
of ADMs, many ADMs do not increase monoamine levels when 
averaged across the whole rodent brain, yet dual MAO-A/B inhibi-
tors are powerful enough to do so (Campbell and Marshall, 1974; 
Fuller et al., 1974; Renard et al., 2004; Bano et al., 2010). In one 
study, a single dose of phenelzine increased whole brain levels of 
5-HT by 240%, NE by 150%, and DA by 170% (Parent et al., 2000).
In mPFC, dual MAO-A/B inhibitors tend to have greater effect 
than the whole brain average. The inhibition of MAO-A by itself 
increases mPFC levels of 5-HT and NE by 200–300% (Finberg 
et al., 1993; Bel and Artigas, 1995), but the simultaneous inhibi-
tion of MAO-A and MAO-B causes increases of at least 400% (Bel 
and Artigas, 1995; Takahashi et al., 2000; Kitaichi et al., 2010). We 
therefore conservatively assume that phenelzine and selegiline (at 
dual inhibition doses) increase mPFC monoamine levels by 400% 
above baseline (Table 1). However, since we do not have precise 
mPFC measurements for phenelzine and selegiline, for our analyses 
we capped the maximum perturbational impact of ADMs at 400%. 
We label the perturbational effect of a drug for each monoamine 
as follows: p5HT (for serotonin), pNE (for norepinephrine), and 
pDA (for dopamine).
The perturbational effects of other ADMs generally correspond 
to the class to which they belong, but there are exceptions and, more 
importantly, differences in degree. The selective serotonin reuptake 
inhibitors (SSRIs) selectively bind to the serotonin transporter, and 
so they tend to increase cortical levels of serotonin. The effects of 
citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline on 
mPFC monoamine levels were assessed in a single study (Bymaster 
et al., 2002). Fluoxetine is unique among the SSRIs in that it also 
increases NE and, to a lesser extent, DA in the mPFC (Bymaster 
et al., 2002; Stahl, 2008). The mechanism is not by reuptake block-
ade, but by antagonism of 5-HT2C receptors (Stahl, 2008). While 
we lack microdialysis data for escitalopram in the 10–15 mg/kg 
range, escitalopram is the active S-enantiomer of citalopram (Stahl, 
2008), so we use the same perturbational values as for citalopram.
The serotonin norepinephrine reuptake inhibitors (SNRIs) selec-
tively bind to both the 5-HT and NE transporters, although, as a 
class, they tend to have greater affinity for the 5-HT transporter 
than the NE transporter. ADMs that inhibit NE reuptake also tend 
to increase prefrontal levels of DA to some degree because there 
are few DA transporter molecules in the prefrontal cortex, so DA 
has a tendency to diffuse widely from the synapse (Stahl, 2008). 
DA eventually gets taken back into neurons by the NE transporter, 
which has a higher affinity for DA than NE (Stahl, 2008). We relied 
on several studies (Kihara and Ikeda, 1995; Koch et al., 2003; Marien 
et al., 2007; Weikop et al., 2007) to get data on the mPFC monoamine 
effects of the SNRIs used in discontinuation studies –  desvenlafaxine, 
duloxetine, milnacipran, and venlafaxine. Venlafaxine does not have 
much effect on NE at 15 mg/kg, but it has a larger effect at 40 mg/kg 
(Koch et al., 2003). The discontinuation studies of venlafaxine use 
doses that are much higher than the recommended dose, so we use 
the data for 40 mg/kg. We lacked microdialysis data for desvenlafax-
ine, but it is the active metabolite of venlafaxine (Stahl, 2008). In the 
discontinuation study of desvenlafaxine, it was also administered at 
doses that are much higher than the recommended dose, so we use 
the same perturbational values as for venlafaxine.
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From each study, we extracted information on a number of vari-
ables that were either directly relevant to our hypotheses, or were 
important covariates to control for.
Demographic variables (age, sex)
We coded each study for the average age of patients (variable 
name = age), and for the proportion of patients who were women 
(variable name = sex), who were randomized to placebo. Two stud-
ies did not report the average age or sex composition of the patients 
randomized to placebo (Doogan and Caillard, 1992; Montgomery 
et al., 1993), so we took the demographic characteristics of all those 
who were subject to randomization instead (Doogan and Caillard, 
1992; Montgomery et al., 1992). Five studies did not report any 
information on the age of the sample, and two of these studies did 
not provide any information on the sex composition of the sample 
(see Table A1 in Appendix).
Depression history (dephx)
In principle, people with greater histories of depression could be at 
a greater risk of relapse (Kendler et al., 2000). We therefore coded 
each study for the minimum number of prior episodes required for 
entry into the study (variable name = dephx). Where not reported, 
we assumed no restriction.
Treatment resistance (txresist)
In principle, patients who are more resistant to pharmacological 
treatment could be at greater risk of relapse (Rush et al., 2006). We 
therefore coded each study for whether treatment resistant patients 
were targeted. Studies were coded as involving treatment resistant 
patients if they included hospitalized patients, or targeted patients 
with chronic or atypical depression (variable name = txresist).
Drug variables (class, half-life)
Characteristics of ADMs other than their perturbational effects 
on mPFC monoamine levels could, in principle, be predictors of 
the risk of relapse. The elimination half-life of the drug is thought 
to be pharmacologically important, so we included it in some of 
our analyses (variable name = half-life) (see Table 2). We do not 
use the half-lives of phenelzine or selegiline as they irreversibly 
bind to monoamine oxidase, so effects may last for 2 weeks after 
discontinuation (Lemke et al., 2010). We took all half-life values 
from Sadock and Sadock (2005), using the value of the parent 
compound or its longest acting active metabolite. Where a range 
in half-life was reported, we took the midpoint.
Treatment duration (txdur)
The duration of acute treatment with an ADM before transi-
tion to placebo could potentially be an important predictor of 
the risk of relapse, as discussed in the introduction. Ideally, each 
study would have a clearly defined treatment period, which is 
the time from the onset of ADM initiation to randomization to 
placebo (variable name = txdur). Unfortunately, patients were 
subjected to treatment for varying time periods in three of the 
MAOI studies (Davidson and Raft, 1984; Harrison et al., 1986; 
Stewart et al., 1997) and four of the TCA studies (Mindham et al., 
1973; Coppen et al., 1978; Cook et al., 1986). For these studies, 
focusing on these special populations. We did not exclude studies 
in which patients were diagnosed with other comorbid conditions, 
such as anxiety disorder or diabetes (Lustman et al., 2006) provided 
they met all other criteria.
Second, each study had to have an initial period of ADM treat-
ment followed by randomization to continued treatment with 
ADM or placebo under double-blind conditions. We allowed 
studies with multiple treatment phases, provided ADM treat-
ment was continuous from the beginning of the study until 
discontinuation.
Third, we excluded any study that did not involve at least one of 
the major ADM classes – MAOI, TCA, SNRI, or SSRI.
Fourth, we excluded any study in which multiple ADMs from 
different classes were simultaneously administered to the same 
individuals because we were interested in isolating the effects of 
individual drug classes. We did not allow the sequential administra-
tion of different ADMs, because they have different perturbational 
effects.
Fifth, we excluded any study in which patients also received 
psychotherapy because it has been shown to influence relapse rates 
after discontinuation.(Hollon et al., 2006).
Sixth, to avoid double-counting, we excluded any report that 
was a re-analysis of data already included in the analysis.
We included part of a study in which patients were given fluox-
etine for 12 weeks and then randomized to one of four branches 
(Reimherr et al., 1998): (1) placebo for the duration of the study; 
(2) continued treatment with fluoxetine for 14 weeks before assign-
ment to placebo; (3) continued treatment with fluoxetine for an 
additional 36 weeks followed by placebo; and (4) continued treat-
ment with fluoxetine for the duration of the study. We include the 
relapse results from only the first assessment period (12 weeks after 
randomization), because this was the only assessment in which all 
subjects in the placebo group had been treated with fluoxetine for 
the same period of time.
We excluded another study (Eric, 1991) because it was a con-
ference abstract that provided a preliminary report of an ongo-
ing study. Consequently, important information was missing 
(e.g., average age, proportion of patients who were women), and 
it appeared to be a preliminary report of a later published study 
(Montgomery and Dunbar, 1993).
Search strategy
Our search strategy involved two steps. First, we used four meta-
analyses of discontinuation studies (Viguera et al., 1998; Geddes 
et al., 2003; Kaymaz et al., 2008; Glue et al., 2010) and a recent 
meta-analysis of extension studies (Zimmerman et al., 2007) 
that used rigorous search criteria as baseline sources. Second, 
we conducted searches of the Web of Science database covering 
1965 until October 8, 2010. To search for discontinuation studies, 
we used the keywords “antidepress* and placebo and (relapse or 
recurren*) and (discontinu* or mainten* or continua*).” Then, we 
conducted similar searches substituting specific drugs for “anti-
depress*” (e.g., “sertraline,” “phenelzine,” “amitriptyline,” etc.). 
To search for extension studies, we used the keywords “antide-
press* and placebo and (relapse or recurren*) and (mainten* 
or continua*) and extension,” The flow diagram for the search 
procedure is in Figure 1.
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24 weeks are referred to as being equal to 6 months, which only 
makes sense if months are considered 4 week periods. For this 
reason, when time periods are reported in months, we assume 
that each month is equal to 4 weeks.
Dropout rate during treatment (droprate)
Patients may drop out of discontinuation and extension studies, 
most commonly because they fail to remit or because they have 
adverse effects from the treatment. This could be an important 
covariate influencing the relapse rate. In principle, the people who 
drop out could be more vulnerable to relapsing, leaving patients 
who remain in the sample more resistant to relapse. We calculated 
the proportion of patients who dropped out of each study during 
the treatment phase as the number of patients who dropped out 
divided by the total number of patients who entered the study (vari-
able name = droprate). Ten studies lacked information on dropout 
rate (see Table A1 in Appendix).
Relapse risk period (riskper)
The studies also varied in the period of time after randomiza-
tion to placebo during which patients were to be monitored 
for relapse. This could be an important predictor of relapse, 
with longer monitoring periods associated with a greater risk 
of relapse. As with treatment duration, this is often reported 
we used the average treatment period or the midpoint in the 
range. For one TCA study, the only information available was 
that acute treatment persisted for 6 weeks after remission of the 
index episode (Coppen et al., 1978). Since there is a therapeutic 
delay of several weeks for all ADMs, we assumed a treatment 
period of 10 weeks. Time periods are usually reported in weeks. 
FiguRE 1 | Flow diagram of the search strategy.
Table 2 | Half-lives of different antidepressant drugs.
Drug  Class  Half-life (hours)
Milnacipran SNRI  8
Venlafaxine SNRI  10
Desvenlafaxine SNRI  10
Duloxetine SNRI  12
Imipramine TCA  17 .5
Fluvoxamine SSRI  19.5
Desipramine TCA  20
Paroxetine SSRI  21
Amitriptyline TCA  25
Escitalopram SSRI  29.5
Citalopram SSRI  35
Clomipramine TCA  37 .5
Nortriptyline TCA  37 .5
Sertraline SSRI 83
Fluoxetine FLX 240
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the number of weeks that DSM-IV criteria must be satisfied, 2 for 
the number of weeks that HRSD > 13, 2 for the number of weeks 
that patients must have CGI-S ≥ 3, and 2 for the number of weeks 
that the CGI-S score must be elevated by 2 points above the baseline 
score). The other study (Keller et al., 1998) would receive a rating of 
11 (4 for the number of weeks that DSM-IV criteria must be satis-
fied, 2 for the number of weeks that patients must have a CGI-S ≥ 4, 
2 for the number of weeks that a patient must have a CGI-I ≥ 3, 2 
for the number of weeks that there must be a 4 point increase in 
HRSD score over that of the maintenance phase, and 1 for confir-
mation by a senior investigator). These studies are clearly outliers. 
Moreover, retaining these scores could be misleading if some of the 
additional hurdles were redundant and had little impact on relapse 
rates. We therefore considered a range of stringency scores of 5–8 
for these studies, with the minimum value reflecting the fact that 
their relapse definitions were more stringent than those of other 
studies. All reported results are based on stringency scores of 5. 
Unless otherwise stated, results do not change significantly with 
different stringency scores.
Relapse rate (relrate)
We calculated the relapse rate (variable = relrate) as the proportion 
of patients who had been randomized to placebo who satisfied 
relapse criteria over the relapse risk period. It was not uncommon 
for the authors of a study to report in the text of the paper a relapse 
number that was lower than the number that could be derived 
from the Kaplan–Meier survival curve (Montgomery et al., 1993; 
Robert and Montgomery, 1995; Hochstrasser et al., 2001; Rickels 
et al., 2010). This occurred because the study authors were, for some 
reason, analyzing relapse disparities between the Drug–Drug and 
Drug–Placebo groups at a time point before the end of the relapse 
risk period. This may not have been an unreasonable thing to do for 
those studies, but for the purposes of this analysis it is important 
to understand precisely how many relapses occurred over a specific 
interval. In such situations, we took the relapse number from the 
Kaplan–Meier survival curves for the relapse risk period that the 
authors reported in their study.
IMPutatIon of MIssIng values
As discussed above, some studies did not provide information about 
the average age, sex composition, or the dropout rate during acute 
treatment. We assumed that this data were missing at random, 
which means that the missing data may depend on variables that are 
known, but not on unknown variables. Under such circumstances, 
it is reasonable to use multiple regression to impute the missing 
data based on the data for which information is available (Little and 
Rubin, 1989), which we did using IVEware for SAS (Raghunathan 
et al., 2002). We used the following variables to impute values: year 
in which the report was published, txresist, dephx, stringency, the 
specific antidepressant, ADM class, the perturbational scores for 
each of the monoamines in mPFC, relapse rate, txdur, and riskper.
Often, a missing data point represents a person about whom a 
piece of information is missing. In this case, imputation involves 
using regression to predict the unknown information based on all 
the known information in the entire sample plus a stochastic ele-
ment to represent the fact that the missing information cannot be 
in weeks. We convert such time periods into 30-day months. 
When reported in months, we assumed that each month was 
equivalent to 4 weeks.
Stringency of criteria for defining depressive relapse (stringency)
We do not distinguish between patients who experienced a recur-
rence (onset of a new episode) from those who relapsed back into 
their index episode. For consistency, we refer to all lapses of remis-
sion as relapses, though some may be recurrences.
As discussed in the introduction, the stringency of criteria used 
to define a relapse (hereafter, stringency) should be an important 
negative predictor of the relapse rate. Commonly used tools for 
assessing depressive symptoms included the Hamilton Rating 
Scale for Depression (HRSD; Hamilton, 1960), the Clinical Global 
Impression-Improvement (CGI-I) or –Severity (CGI-S) scales 
(Guy, 1976), the Montgomery–Asberg Depression Research Scale 
(Montgomery and Asberg, 1979), DSM-III or DSM-IV criteria, 
the Beck Depression Inventory (Beck and Beamesderfer, 1974), 
or clinical judgment. Studies could vary on the number of these 
assessment tools and the cutoff scores used to diagnose a relapse. 
Additionally, studies varied on the duration of time that symptoms 
must persist.
Taking into account the stringency of relapse criteria is diffi-
cult as the variety of qualitatively different criteria prohibits easy 
comparison. However, there are strong a priori reasons to believe 
that stringency must be an important variable that affects relapse 
rates. Simply put, the more stringent the criteria that a study uses 
to define a relapse, the more difficult it will be for patients to meet 
the criteria, and overall relapse rates should be lower.
We operationalize stringency as the number of assessment hur-
dles that must be passed for an episode to be deemed a relapse. This 
has the drawback of ignoring cutoff differences. Thus, a study that 
defines relapse as requiring a HRSD > 18 would be given the same 
stringency score as a study that requires a HRSD > 12. However, 
there are very few studies that could be directly compared solely on 
the basis of differences in cutoff scores, so it is an impractical metric.
The advantage of using the number of assessment hurdles is 
that it is an objective way for us to compare the studies, and it leads 
to a natural way of taking into account differences in the require-
ments for duration of symptoms. For instance, if a study defines 
a relapse as requiring a HRSD > 15 and a CGI-S > 3 for 2 weeks 
in a row, then we assign it a stringency rating of four (one HRSD 
assessment and one CGI-S assessment must be passed each of the 
2 weeks). When a study uses a number of criteria paths by which a 
patient can be designated as relapsed, we give priority to the path 
with the shortest duration requirement, then to the path with the 
fewest number of assessments that must be passed.
Two of the authors, Paul W. Andrews and Lisa J. Halberstadt, inde-
pendently rated each study for the stringency of the relapse criteria. 
Agreement between the two ratings was very high: kappa = 0.782, 
weighted kappa = 0.903, and tetrachoric correlation = 0.986. 
Differences between the two ratings were then reconciled.
Nearly all the studies had stringency scores ranging from 1 to 
4. However, two studies used a complex combination of assess-
ments and symptom duration requirements (Keller et al., 1998; 
Amsterdam and Bodkin, 2006). Using our strict definition for 
the number of assessment hurdles that must be passed, one study 
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point is not an individual but a study in which a summary statis-
tic – the average age, sex composition, or dropout rate – is missing. 
We want to impute the missing summary statistics (rather than 
the missing data of an individual) based on the summary statistics 
from all the studies that were available. However, imputing with a 
stochastic component would introduce far more variability into the 
summary statistic than actually existed. For this reason, we imputed 
without stochasticity. Due to the non-stochasticity, the estimates for 
analyses in which imputed data were used are slightly more precise 
(their SE are smaller) than they should be. However, since age, sex, 
and dropout rate were not significant predictors of the relapse rate, 
this problem would not apply to our best-fitting model.
statIstIcal analysIs
We conducted weighted least squares regression analyses using 
PROC REG in SAS on both the non-imputed and the imputed 
datasets. Since the results were not significantly different, we only 
report the results from the imputed data. All studies were weighted 
by the inverse of the variance for the proportion of patients with 
a relapse during the discontinuation phase. To avoid over-fitting 
problems that can arise from having more variables than studies, we 
constructed a best-fitting model. We did this by examining how the 
removal of each variable influenced the adjusted R2, keeping all the 
other variables in the model. We then eliminated the one variable 
that improved the fit the most. This procedure was repeated with 
the remaining variables until all model variables were significant or 
their elimination could not improve the fit. In all reported models, 
the results have been examined for, and are unaffected by, influen-
tial data points. No reported models showed signs of over-fitting.
results
Forty-six papers met inclusion criteria, constituting 49 samples 
and 3,454 patients (Klerman et al., 1974; Coppen et al., 1978; Stein 
et al., 1980; van Praag and de Haan, 1980; Davidson and Raft, 1984; 
Harrison et al., 1986; Montgomery et al., 1988, 1993, 1998, 2004; 
Georgotas et al., 1989; Robinson et al., 1991; Doogan and Caillard, 
1992; Claghorn and Feighner, 1993; Montgomery and Dunbar, 
1993; Anton et al., 1994; Robert and Montgomery, 1995; Bremner 
and Smith, 1996; Entsuah et al., 1996; Kocsis et al., 1996, 2007; 
Stewart et al., 1997; Keller et al., 1998; Reimherr et al., 1998; Terra 
and Montgomery, 1998; Reynolds et al., 1999; Alexopoulos et al., 
2000; Rouillon et al., 2000; Schmidt et al., 2000; Gilaberte 
et al., 2001; Hochstrasser et al., 2001; Klysner et al., 2002; Wilson 
et al., 2003; Detke et al., 2004; Simon et al., 2004; Amsterdam 
and Bodkin, 2006; Kamijima et al., 2006; Lustman et al., 2006; 
McGrath et al., 2006; Perahia et al., 2006, 2009; Gorwood et al., 
2007; Cheung et al., 2008; Dobson et al., 2008; Emslie et al., 2008; 
Rickels et al., 2010). The information extracted from each study 
is listed in Table A1 in the Appendix. In Figure 2, we provide a 
forest plot of the relapse rates of individual studies, grouped by 
the particular ADM used, and ADMs in the same class are organ-
ized alphabetically.
Table 3 provides basic summary statistics. The PBO studies had 
the unadjusted relapse rate, which is consistent with our first pre-
diction. However, this is also consistent with the possibility that 
the PBO studies tended to include patients with a lower risk of 
FiguRE 2 | Forest plot of the relapse rate and 95% confidence interval for 
each study meeting inclulsion criteria. 
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negative  correlation between the stringency variable and the relapse 
rate. The stringency variable also shows a marginally significant 
relationship between the risk period and treatment duration, 
suggesting that they could be potential confounds for each other. 
Finally, the risk period and treatment duration are significantly cor-
related with each other, suggesting that they could also be potential 
confounds for each other.
PredIctors of the droPout rate
To formally test whether there is a potential selection bias problem 
in the PBO group due to a higher dropout rate during acute treat-
ment, we regressed the dropout rate on the ADM classes and tested 
for a formal contrast of the ADM classes against the PBO class. We 
included as covariates the average age, the proportion of patients 
who were female, the duration of acute treatment, whether treat-
ment resistant patients were targeted in the study, and the minimum 
number of depressive episodes required for entry. The contrast was 
significant, p = 0.003, indicating that the ADM classes had lower 
dropout rates than the PBO group. Additionally, the duration of 
acute treatment was a positive predictor of dropout rate, β =+0.023, 
SE = 0.010, p = 0.03. Subsequent analysis showed that it was driven 
by the ADM classes (not the PBO class), suggesting that longer 
drug treatment caused higher dropout, possibly due to adverse 
drug effects. In short, these results suggested that there could be a 
potential selection bias problem in the PBO studies.
does the droPout rate PredIct the relaPse rate?
Next, we regressed the relapse rate on the dropout rate to see 
whether the potential selection bias problem was affecting the 
relapse rate. By itself, dropout rate was not a significant predictor, 
β = −0.213, SE = 0.225, p = 0.35. We then added covariates (age, sex, 
txresist, txdur, dephx), but the dropout rate was still not significant, 
β = −0.262, SE = 0.257, p = 0.32.
Even though we had no evidence that the dropout rate – by itself 
or in conjunction with covariates – was a predictor of the relapse 
rate, we included it as a covariate in our subsequent analyses unless 
otherwise indicated. We also included the interaction of dropout 
rate with a binary treatment variable (PBO or ADM), but it was not 
significant in any of the analyses, so we do not report it.
relapse (e.g., patients were less likely to have a prior history of 
depression, or they were more resistant to pharmacological treat-
ment). Moreover, the PBO studies had the highest dropout rate 
during acute treatment, while the ADM classes had similar dropout 
rates. The dropout rate pattern suggests a potential selection bias 
problem for the PBO group, so we include the dropout rate as a 
covariate in all our regression analyses, unless otherwise specified. 
The SSRI studies had the second highest raw relapse rate, after the 
TCAs, while the MAOIs had the second lowest raw relapse rate of 
the ADM classes.
correlatIons
For the ADM discontinuation studies, we examined the bivariate 
correlations between the continuous and count variables (Table 4). 
The perturbational effects of NE and DA are both significantly 
correlated with the relapse rate, but the correlation between pNE 
and pDA approaches unity, indicating a collinearity problem. The 
perturbational effect of 5-HT is not significantly correlated with 
the relapse rate, but it is related to other variables that could be 
potential confounds (risk period, treatment duration). Partially 
Table 3 | The number of samples (N), the dropout rate during the 
treatment phase, and the relapse rate after randomization to placebo 
for each ADM class.
Class N Percentage 
of dropout 
(treatment)
No. of 
patients on 
placebo
No. of 
patients who 
relapsed
Percentage 
of relapse 
PBO 7 65.4a 437 108 24.7
SSRI 19 49.0 1,659 743 48.7
SNRI 7 47 .7 962 404 42.0
TCA 9 46.5b 178 99 55.6
MAOI 6 51.6c 218 99 45.4
Overall 49 51.2d 3,454 1,453 42.1
aBased on five of the seven samples.
bBased on five of the nine samples.
cBased on two of the six samples.
dBased on 39 of the 49 samples.
Table 4 | The bivariate correlations between the continuous and count variables.
  1  2  3  4 5 6  7 8  9  10
1.  p5HT  1              
2. pNE  −0.15  1            
3. pDA  −0.09 0.94d  1          
4. Age  −0.06  −0.12  −0.10  1        
5. Sex  0.01  −0.05  −0.02  0.13 1         
6. Droprate  0.02  0.17  0.14  −0.12  −0.14 1       
7 . Riskper  −0.30† 0.02  0.07  0.44 0.04  −0.03 1     
8. Txdur  −0.18 0.20 0.14  0.19  −0.18  0.24 0.48b  1  
9. Stringency  −0.02 0.18 0.14  0.00  −0.03  0.15 0.28†  0.32a  1 
10. Relrate  0.07  0.53c  0.60d  0.00  −0.11  0.14 0.12  0.12  −0.30† 1
†p < 0.10, ap < 0.05, bp < 0.01, cp < 0.001, dp < 0.0001.
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cance in the entire sample when covariates (age, sex, txresist, dephx, 
droprate, txdur, riskper) are included, β = −0.050, SE = 0.019, p = 0.01.
does the Pbo grouP have a lower relaPse rate than the adM 
classes?
Our first prediction was that the PBO group would have a lower 
relapse rate than that of the ADM studies, and this was supported by 
the summary statistic results. To formally test this, we constructed a 
binary treatment variable (0 = PBO, 1 = the ADM classes). We then 
regressed the relapse rate on this treatment variable. The treatment 
variable was significant, β = 0.277, SE = 0.067, p = 0.0001, indicating 
that the PBO group had a significantly lower relapse rate than the 
ADM classes. Inclusion of the stringency variable only increased the 
significance of the results. As discussed above, the lower relapse rate 
of the PBO group could be due to a selection bias problem in which 
more relapse–vulnerable patients dropped out during acute treatment, 
or because more patients in the PBO studies were more vulnerable to 
relapse at the outset. To formally test this, we included as covariates 
the minimum number of depressive episodes required for entry into 
the study, whether treatment resistant patients were targeted, and the 
dropout rate during the acute treatment phase. None of the sample 
characteristic variables were significant, while the treatment variable 
remained significant, β = 0.342, SE = 0.080, p = 0.0001. The inclusion of 
other covariates also did not influence the significance of this variable.
do the PerturbatIonal ProPertIes of adMs PredIct the 
relaPse rate?
Our second prediction was that the perturbational properties of 
ADMs on mPFC monoamine levels would be positive predictors 
of the relapse rate. To formally test this, we regressed the relapse 
rate on the perturbational effects on 5-HT and NE. (Since the per-
turbational effects on NE and DA are highly collinear, we do not 
does the strIngency varIable negatIvely PredIct the relaPse 
rate?
The correlational results suggested that the stringency of relapse 
criteria could be an important negative predictor of the relapse 
rate. To give a visual presentation of this, we graphed the relapse 
rate as a function of the stringency variable for each class (see 
Figure 3). Within each class, the relapse rates tend to decline with 
stringency, suggesting that stringency is an important covariate. 
Moreover, the MAOIs have the highest relapse rates at each level 
of stringency. It is only for a stringency score of 5 or greater that 
the MAOI relapse rate drops off substantially. This is actually due 
to a single study (Amsterdam and Bodkin, 2006) with the sec-
ond highest score on the stringency variable in our meta-analysis 
(stringency score = 8). Comparison of this figure with Table 3 sug-
gests that, consistent with our second prediction, the ADMs with 
the greatest perturbational effects may actually have the highest 
relapse rates, but these can be obscured if one does not take the 
stringency of relapse criteria into account. To help illustrate this 
point further, we separated out the fluoxetine (FLX) studies from 
the other SSRIs. As discussed above, fluoxetine is unique among 
the SSRIs in that it causes NE and DA to increase in the mPFC 
through a mechanism other than reuptake blockade, which makes 
it substantially more perturbational than other SSRIs. Consistent 
with our second prediction, the fluoxetine studies tend to have 
higher relapse rates than the other SSRIs. In fact, the relapse rates 
of the fluoxetine studies seem to be more comparable to that of 
the SNRI and TCA studies – other ADM classes that influence 
NE and DA.
To formally test our prediction, we regressed the relapse rate on 
the stringency variable. The stringency variable, by itself, is only a 
marginally significant negative predictor of the relapse rate when all 
49 samples are analyzed, β = −0.035, SE = 0.018, p = 0.06. However, it 
reaches significance when only the 42 ADM discontinuation samples 
FiguRE 3 | unadjusted proportions (with SE bars) of patients with a relapse after discontinuation (to placebo) (y-axis) as a function of the stringency of 
the definition of relapse (x-axis) for each ADM class.
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ADMs perturbed DA levels in the mPFC. Given the high degree 
of collinearity between the perturbational effects of ADMs on NE 
and DA, we prefer the 5-HT/NE model over the 5-HT/DA model 
because the evidence for the involvement of NE in depression is 
stronger.
While the results are robust, their implications depend on their 
interpretation, so we first discuss several potential confounds. Is 
it possible, for instance, that the results do not reflect the risk of 
relapse, but rather withdrawal symptoms? The discontinuation of 
ADM can cause withdrawal symptoms (also known as discontinua-
tion syndrome) that are unrelated to relapse, but may sometimes be 
mistaken for relapse (Haddad, 1997). Such mistakes are more likely 
with untrained physicians (Haddad, 1997), so it should be less of a 
problem in ADM discontinuation studies where trained psychia-
trists are employed to evaluate putative cases of relapse. Regardless, 
drugs with longer half-lives are less likely to show discontinuation 
syndrome (Michelson et al., 2000; Fava, 2006). If discontinuation 
syndrome were being mistaken for relapse, then drugs with longer 
half-lives should have lower relapse rates. To test this possibility, we 
added half-life to the best-fitting model and eliminated the pertur-
bational variables (results not shown). The resultant model did not 
fit as well, and, in fact, half-life was a significant positive predictor 
of relapse rate. This is because drugs with stronger perturbational 
effects on 5-HT tend to have longer half-lives. We therefore have 
no evidence that withdrawal symptoms were mislabeled as relapses.
There is some evidence that ADM treatment resistant patients 
may have higher relapse rates (Rush et al., 2006). Is it possible that 
studies using ADMs with stronger perturbational properties had 
higher relapse rates, not due to the pharmacological properties of 
the drugs used, but because they also had higher proportions of 
treatment resistant patients participating in them? There are two 
ways this could happen. First, studies using stronger ADMs could 
have been more likely to target treatment resistant patients at the 
outset. Second, the characteristics of patient samples in discontinu-
ation studies may change during treatment due to dropouts caused 
by the treatment, causing a potential selection bias problem.
analyze them at the same time.) We included as covariates average 
age, the proportion of women in the sample, the minimum number 
of prior episodes required for entry, whether treatment resistant 
patients were targeted, the dropout rate during acute treatment, 
the duration of acute treatment, the length of the risk period, and 
the stringency of relapse criteria. We report the estimates of this 
model in Table 5, Model I. The perturbational effects of ADMs 
on 5-HT and NE were both significant positive predictors of the 
relapse rate, as was stringency and the duration of the risk period.
Next, we excluded the PBO studies and re-ran the analyses, the 
results of which are in Table 5, Model II. Comparing Model II with 
Model I shows that the estimates for Model II are well within the 
95% confidence limits of the estimates for Model I. Thus, includ-
ing the PBO studies does not fundamentally change the parameter 
estimates – they only increase the power.
Then, we included the PBO studies and excluded the MAOI 
studies, to determine how the parameter estimates were affected 
by the MAOI studies. The estimates for this model (not shown) 
were also well within the 95% confidence limits of the Model I 
estimates. Additionally, the perturbational variables for 5-HT and 
NE, and the risk period and stringency variables, were all statisti-
cally significant. Thus, the inclusion of the MAOI studies also does 
not fundamentally change the parameter estimates.
Using the entire sample, we report the best-fitting model in 
Table 5, Model III. Only the perturbational variables for 5-HT and 
NE, the stringency variable, and the risk period remained in the 
model, but they still explained nearly 60% of the variance.
Finally, we re-ran each of these analyses using the perturbational 
variable for DA in place of NE (results not shown). They all fit nearly 
as well, as might be expected from their collinearity.
dIscussIon
We found robust support for our predictions. The risk of relapse 
after ADM discontinuation was higher than the risk of relapse after 
remission on placebo. Moreover, the risk of relapse was after ADM 
discontinuation was positively predicted by the degree to which 
ADMs perturbed 5-HT and NE levels in the rodent mPFC. The 
Table 5 | Parameter estimates and SE from the weighted least squares analyses (see text).
Variables  Model i  Model ii  Model iii
  Estimate SE  95%  Ci  Estimate Estimate SE
P5HT 0.00063b  0.00018  0.00026, 0.00099  0.00043†  0.00061c  0.00016
pNE 0.0011d  0.00024  0.00065, 0.0016  0.0010c  0.0012d  0.00022
Age  −0.0015 0.0024 −0.0065, 0.0035  −0.00013  
Sex  −0.00063 0.0023  −0.0052, 0.0040  −0.0036  
Txresist  −0.022 0.0604  −0.144, 0.100  −0.0267  
Dephx  0.0087 0.0382  −0.0687 , 0.0860  0.0293   
Droprate  −0.0449 0.1928  −0.4352, 0.3455  0.2448   
Txdur  0.0176 0.0144 −0.0116, 0.0468  0.0085   
Riskper 0.0091a  0.0043  0.00042, 0.0178  0.0049† 0.0114c  0.0031
Stringency  −0.1025d  0.0179  −0.1386, 0.0664  −0.1062d  −0.0946d  0.0161
R2  0.618       0.586
Adj. R2  0.518       0.548
†p < 0.10, ap < 0.05, bp < 0.01, cp < 0.001, dp < 0.0001.
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to be passed before an increase in symptoms was deemed to be a 
relapse. As expected, this variable was a significant negative predic-
tor of the relapse rate, and it generally improved the explanatory 
power of other variables in our analyses (results not shown), sug-
gesting that the failure to take this variable into account can obscure 
findings. Nevertheless, our findings are necessarily correlational.
Is behavIoral dePressIon In rodents hoMologous to clInIcal 
dePressIon In huMans?
We could not use data on how ADMs perturb monoamine levels in 
humans. Such data do not exist because they require highly invasive 
techniques. Consequently, we used evidence on the perturbational 
effects in rat mPFC, which has been found to play a special role in 
processing information about stressors and triggering depressive 
symptoms in response to repeated, uncontrollable shock (Amat 
et al., 2005). ADMs have dramatically different effects on monoam-
ine levels in different brain regions (Dawson and Li, 2003; Valentini 
et al., 2004, 2005), so the gambit was that the perturbational effects 
in the rodent mPFC would predict the risk of relapse after ADM 
discontinuation in humans. This need not have been true.
Indeed, there are ongoing debates about whether behavioral meas-
ures of depression in rodents are good models of human depression 
(Nestler et al., 2002; Anisman and Matheson, 2005; Kalueff et al., 
2007). These debates are, at least implicitly, about whether rodent 
models are homologous to depression in humans. Consequently, 
arguments tend to focus on whether the models induce behavioral 
symptoms in rodents that map onto depressive symptoms in humans, 
and whether the symptoms are alleviated by ADM treatment.
Our results show that the degree to which an ADM perturbs 
monoamines in the mPFC predicts the risk of depressive relapse 
in humans after discontinuation of the ADM. In other words, the 
region that predicts behavioral depression in rats also predicts 
depression in humans, which provides further evidence that rodent 
and human depression are homologous. Moreover, these results 
suggest that the rodent mPFC may be homologous to a region in 
the human brain that plays a similar role in clinical depression. 
One possible candidate is the VLPFC, of which the mPFC has been 
argued to be a structural and functional homolog (Kesner, 2000). 
The VLPFC has been implicated in clinical and subclinical depres-
sion and may play an important role in depressive rumination 
(Drevets, 1998; Andrews and Thomson Jr., 2009).
are the syMPtoMs currently used to dIagnose Mdd better 
characterIzed by dIsorder or adaPtatIonIst hyPotheses?
Our results are also relevant to debates about whether the symp-
toms used to diagnose MDD are better characterized by disorder or 
adaptationist hypotheses. Of course, we cannot definitively answer 
this question. Our results are most relevant to claims that depressive 
episodes that meet diagnostic criteria for MDD are monoaminergic 
disorders.
If every disorder is to be understood as involving a malfunc-
tion in some adaptation (Wakefield, 1992), then mapping out the 
evolved structure and operation of adaptations can facilitate the 
identification of disorder by revealing the precise points where 
malfunction can occur. As discussed above, homeostatic mecha-
nisms have sensor and feedback components, and some also have 
A related issue is whether the PBO class (denoted by the Placebo–
Placebo arms of the extension studies) was fundamentally differ-
ent from the other classes (denoted by the Drug–Placebo arms 
of the ADM discontinuation studies). For instance, perhaps the 
PBO studies targeted fundamentally different samples at the outset, 
or perhaps they had higher dropout during the acute treatment 
phase so that patient populations were substantially different by 
the beginning of the extension phase. Consistent with this, the PBO 
studies did have a higher dropout rate and a lower relapse rate than 
the ADMs as a group. Of course, this result might also be expected 
if the PBO studies were quantitatively different only because they 
were on one end of the perturbational continuum.
To deal with these issues in our analyses, we included two vari-
ables as covariates that captured differences in the initial patient 
populations: whether treatment resistant patients were being tar-
geted, and the minimum number of depressive episodes required 
for entry into the study. Neither variable was significant in any 
of our analyses, and their inclusion did not change the statistical 
significance of any result. We also included the dropout rate during 
acute treatment because the PBO studies had significantly higher 
dropout rates, and the dropout rate in the ADM discontinuation 
studies was positively associated with the duration of treatment. 
Both findings suggested that the dropout rate during treatment 
might be a proxy for the degree of selection bias at discontinua-
tion. If selection bias problems were driving the lower relapse rate 
in the PBO studies or the relationship between relapse rate and 
perturbational variables, then dropout rate during the treatment 
phase could predict relapse, either as a main effect or in interaction 
with binary treatment status (Placebo vs. Drug). Neither term was 
significant in any of our analyses, nor did they affect the significance 
of any result.
In any event, the strongest reason for inferring that the PBO 
studies were not qualitatively different from the other studies is 
that excluding them did not significantly change the parameter 
estimates of any variables, including the perturbational variables. 
This suggests that the PBO studies simply anchor one end of 
the perturbational continuum and increase the power of our 
analyses. (Similarly, even though we had to make assumptions 
about the prefrontal perturbational effects of phenelzine and 
selegiline based on evidence from other dual MAO-A/B inhibi-
tors, our results did not change significantly if we excluded the 
MAOI studies.)
Another potential confound is that we are only using published 
studies in our meta-analysis. It has been shown, for instance, that 
there is a publication bias of studies dealing with the efficacy of 
ADMs during acute treatment (Turner et al., 2008). For publication 
bias to explain our results, the likelihood of publication would have 
to be related to the perturbational effects of ADMs. This seems to 
us unlikely, but we cannot rule out this possibility.
Other limitations of this meta-analysis highlight difficulties with 
the ADM literature on which it is based. To address the question of 
how ADM discontinuation affects relapse rates, we were forced to 
rely on between-study relapse rates that may be biased by a number 
of other between-study differences, such as how relapse is defined. 
Prior meta-analyses have not dealt directly with this issue, despite 
evidence that definitional criteria affect relapse rates (Montgomery 
and Dunbar, 1993; Keller et al., 1998). We constructed a stringency 
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may lower survivorship (Brandts et al., 1997; Hasday et al., 2000; 
Schulman et al., 2005).
In short, we found no positive evidence to support, and some 
positive evidence to contradict, the claim that most patients diag-
nosed with MDD have a monoaminergic disorder. Nor is there 
any evidence that the current diagnostic reliance on distress and 
impairment accurately identifies depressive disorder. Consequently, 
our results are just as consistent with adaptationist hypotheses, 
although they do not speak to the issue of what function depression 
may have evolved to serve.
clInIcal IMPlIcatIons
Our results have several important clinical implications.
Modest efficacy of ADMs during acute therapy
Hypotheses that depression is caused by a dysregulation in mono-
amine levels were developed based on drugs that lower symptoms 
and had monoaminergic properties, such as blockade of the sero-
tonin transporter or inhibition of the MAO enzymes (Valenstein, 
1998). However, these drugs also have limited efficacy during acute 
treatment (Kirsch et al., 2008; Fournier et al., 2010), which is one 
reason why researchers are investigating the role of other neuro-
chemicals in depression (Krishnan and Nestler, 2008). However, 
even if monoamines are the neurochemical cause of depression, the 
limited efficacy of ADMs could be explained by the development 
of oppositional tolerance.
Maintenance therapy
It is commonly thought that ADM treatment should continue until 
the index episode resolves, else relapse will recur. For this reason, 
maintenance ADM therapy is often recommended for 4–12 months 
or more after the acute management of the index episode (Geddes 
et al., 2003). Nevertheless, there are troubling empirical problems 
with these guidelines. For instance, in naturalistic studies, unmedi-
cated patients have much shorter episodes, and better long-term 
prospects, than medicated patients (Coryell et al., 1995; Goldberg 
et al., 1998; Posternak et al., 2006). Several of these studies have 
found that the average duration of an untreated episode of major 
depression is 12–13 weeks (Coryell et al., 1995; Posternak et al., 
2006). Since acute ADM management of major depression mini-
mally requires several weeks to reduce symptoms, the duration of 
untreated episodes is much shorter than the recommended dura-
tion of ADM therapy. This suggests that ADM therapy may delay 
resolution of depressive episodes.
Current maintenance therapy guidelines are based primarily on 
prior meta-analyses that have found that the relapse rates in the 
Drug–Drug arms of ADM discontinuation studies are consistently 
lower than in the Drug–Placebo arms (Viguera et al., 1998; Geddes 
et al., 2003; Kaymaz et al., 2008; Glue et al., 2010). This is often 
interpreted as evidence that ADM therapy prevents depressive 
relapse. However, our results suggest that oppositional tolerance 
to the ADM contributes to the high risk of relapse in the Drug–
Placebo arms of these studies, which undermines the rationale for 
maintenance therapy. Moreover, if continuous ADM therapy were 
needed until the index episode resolved, then ADM discontinua-
tion studies with longer periods of continuous treatment should 
components for altering the equilibrium level of the parameter. 
To produce oppositional tolerance, the sensor component must be 
able to discern perturbations from equilibrium so that the feedback 
component can produce an oppositional force proportional to the 
degree of perturbation.
Our results support the conclusion that prolonged ADM use 
triggers oppositional tolerance in patients meeting diagnostic 
criteria for MDD. As predicted by an oppositional tolerance 
model, the risk of relapse was higher after ADM discontinuation 
than the unmedicated risk of relapse. Also, the risk of relapse 
after ADM discontinuation was proportional to the perturba-
tional effect of the ADM on rodent mPFC. This result is analo-
gous to the oppositional force produced by a spring, which is 
proportional to the deviation from the equilibrium position. 
Our results therefore provide no evidence of malfunction in 
either the sensor or feedback components of monoaminergic 
homeostatic mechanisms in patients with episodes that satisfy 
diagnostic criteria for MDD.
However, it is possible that there could be some malfunction 
in the component that alters equilibrium monoamine levels. 
Demonstrating malfunction in this component requires more 
than merely showing that the equilibrium point is altered, since 
that is the function of this component. In other words, the claim 
that depression is a disorder in which monoamine levels are too 
high or too low is not simply supported by evidence that mono-
amine levels are altered since this could merely be the conse-
quence of adaptive changes in the equilibrium levels in response 
to stressors. Undoubtedly, the equilibrium altering component 
must malfunction at some rate, but it is not clear that it is mal-
functioning as frequently as current diagnostic criteria suggest. 
Understanding when it is malfunctioning will require greater 
research into the structure and operation of this component in 
response to stress. In any event, our results provide no positive 
evidence of malfunction in the homeostatic mechanisms regu-
lating monoamine levels in people that meet diagnostic criteria 
for MDD.
Of course, our results do not speak to other possible malfunc-
tions in patients who meet criteria for MDD. However, there is 
currently no evidence that the mechanisms regulating other neu-
rochemicals are malfunctioning in patients diagnosed with MDD. 
The conceptual basis for considering an episode of depression to 
be a mental disorder is that it causes significant distress or impair-
ment (American Psychiatric Association, 2000). However, it is clear 
that the body has evolved adaptations for causing significant pain 
and impairment.
For instance, organisms with infection can be incapacitated for 
days, weeks, or months, yet such incapacitation is usually consid-
ered to be an adaptive response to infection (Dantzer, 2001). Since 
mounting an effective immune response requires massive amounts 
of energy (Lochmiller and Deerenberg, 2000; Wolowczuk et al., 
2008), social, sexual, locomotor, or cognitive activity could draw on 
limited energetic resources and interfere with the immune response. 
Consequently, the social, sexual, locomotor, and cognitive incapac-
ity exhibited by sick organisms reflects an adaptive downregulation 
of systems that could otherwise interfere with mounting an effective 
immune response. Consistent with this, there is growing evidence 
that pharmacological disruption of fever, which is the best studied 
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of ADMs to help people wean off such substances might merely 
replace one dependency with another.
Treating depression with multiple psychotropic drugs
Since many patients on antidepressants alone do not achieve full 
remission (Rush et al., 2006), possibly due to oppositional toler-
ance, atypical antipsychotic drugs, and other agents are increasingly 
prescribed to enhance the efficacy of ADMs. Our results suggest that 
the concurrent use of multiple drugs could cause greater monoam-
inergic perturbations, possibly further increasing the risk of relapse 
after they are discontinued.
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have lower relapse rates. This prediction has not been supported 
in any prior meta-analysis of ADM discontinuation studies. We 
also did not find treatment duration to have a protective effect on 
the risk of relapse. Rather, we found a non-significant trend for 
longer periods of continuous ADM treatment to be associated with 
a greater risk of relapse. Maintenance therapy guidelines should 
be re-examined.
Dependency on ADMs
Drugs that promote the risk of relapse or withdrawal upon dis-
continuation can cause dependence on the drug to prevent the 
return of symptoms (Chouinard, 2004). Consequently, such drugs 
must be managed carefully and patients must provide informed 
consent for their use (Bursztajn and Brodsky, 1998). ADMs are 
sometimes prescribed to people with alcohol or illicit drug depend-
encies (Petrakis et al., 2003), because the use of such substances 
to medicate feelings of anxiety and depression is thought to play a 
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Table A1 | Studies that met inclusion criteria.
Sample Age Sex 
(%)
Diagnosis Diagnostic 
criteria
Treatment 
resistant 
patients?
Min. no. 
of prior 
episodes
Criteria for defining relapse Stringency
Anton et al. 
(1994)
NR NR MDD DSM-III-R No 0 Clinical judgment 1
Bremner and 
Smith (1996)
NR 75 MDD DSM-III No 0 HRSD > 16 1
Claghorn and 
Feighner (1993)
41 28 MDD DSM-III No 0 HRSD > 17 1
Detke et al. 
(2004)
44 74 MDD RDC No 0 HRSD within 30% of entry score 
before medication
1
Entsuah et al. 
(1996)
40 71 MDD DSM-III-R No 0 CGI-S > 3 for 2 weeks 2
Montgomery 
et al. (1993)
44 65 MDD DSM-III-R Yes 0 MADRS > 21 1
Montgomery 
et al. (1998)
42 58 MDD DSM-III No 0 HRSD > 15 1
Hochstrasser 
et al. (2001)
42 75 MDD DSM-IV Yes 2 MADRS > 21 + confirm in 3–7 days 2
Klysner et al. 
(2002)
75 72 MDD DSM-IV No 0 MADRS > 21 + confirm in 3–7 days 2
Montgomery 
et al. (1993)
44 65 MDD DSM-III-R Yes 0 MADRS > 21 1
Robert and 
Montgomery 
(1995)
47 69 MDD DSM-III-R No 0 MADRS > 24 + clinical judgment 2
Gorwood et al. 
(2007)
72 79 MDD DSM-IV No 0 MADRS > 21 or lack of efficacy 1
Terra and 
Montgomery 
(1998)
45 78 MDD DSM-III-R No 2 (Clinical judgment + 5 DSM-III-R 
symptoms) + confirm 8 days later
4
Emslie et al. 
(2008)
12 36 MDD CDRS-R No 0 (CDRS-R40 + worsening of 
symptoms for 2 weeks) or clinical 
judgment
1
Gilaberte et al. 
(2001)
44 77 MDD DSM-III-R No 1 DSM-III + ((HRSD > 17/CGI-S > 3) 
for 2 weeks)
3
McGrath et al. 
(2006)
38 55 MDD DSM-IV No 0 CGI-I > 2 for 2 weeks 2
Montgomery 
et al. (1988)
NR NR MDD DSM-III No 1 HRSD > 18 1
Reimherr et al. 
(1998)
41 77 MDD DSM-III-R No 0 (DSM-III-R for 2 weeks) or 
(HRSD > 13 for 3 weeks)
2
Schmidt et al. 
(2000)
42 64 MDD DSM-IV No 0 DSM-IV + (CGI-S > 3 for 2 weeks) 3
Dobson et al. 
(2008)
39 78 MDD DSM-IV No 0 (HRSD > 13 or PSR > 4) for 2 weeks 2
(Continued)
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and Dunbar 
(1993)
48 78 MDD DSM-III-R 
(HRSD18)
No 2 CGI-S > 3 or DSM-III-R (without 
2 week duration) or clinical 
judgment or 2 point increase in 
CGI-S score since prior assessment 
or depressive symptoms for longer 
than 7 days
1
Cheung et al. 
(2008)
16 78 MDD SADS No 0 Clinical judgment 1
Doogan and 
Caillard (1992)
51 69 MDD RDC No 0 CGI-S > 3 1
Kamijima et al. 
(2006)
38 63 MDD DSM-IV No 0 (HRSD > 14 + CGI-I > 3) for 2 weeks 4
Keller et al. 
(1998)
42 69 MDD DSM-III-R Yes 0 [DSM-III for 3 
weeks + CGI-S > 3 + CGI-I > 2 +  
HRSD (4 points greater than 
maintenance score)], each 
confirmed again 1 week 
later) + confirmed by PI
11
Lustman et al. 
(2006)
55 62 MDD DSM-IV No 0 (BDI > 9 for 2 weeks or 
BDI > 15) + DSM-IV
2
Wilson et al. 
(2003)
77 75 MDD DSM-III-R No 0 DSM-III-R + HRSD > 12 2
Perahia et al. 
(2006)
45 78 MDD DSM-IV No 1 CGI-S > 3 + (MINI for 2 weeks) 3
Perahia et al. 
(2009)
48 75 MDD DSM-IV No 2 (DSM-IV + CGI-S > 3) for 2 weeks 4
Rickels et al. 
(2010)
43 68 MDD DSM-IV No 0 HRSD > 15 or CGI-I > 5 1
Rouillon et al. 
(2000)
45 68 MDD DSM-III-R Yes 1 DSM-III-R + HRSD > 17 + need to 
treat
3
Kocsis et al. 
(2007)
43 67 MDD DSM-IV No 2 (HRSD > 12 + HRSD score > than 
50% of baseline score) for 2 
visits + DSM-IV by senior 
investigator
4
Montgomery 
et al. (2004)
44 67 MDD DSM-III-R No 1 CGI-S > 3 1
Simon et al. 
(2004)
41 62 MDD DSM-IV No 0 (DSM-IV + CGI-S > 3) or (CGI-S > 3 
for 2 weeks)
2
Coppen et al. 
(1978)
52 81 Dep MRC Yes 0 Severe enough to be admitted to 
hospital
1
Klerman et al. 
(1974)
38 100 Dep DSM-II No 0 Clinical judgment 1
Stein et al. 
(1980)
42 65 MDD Feighner 
and DSM-III
No 0 Worsening of symptoms for 
3 weeks
3
van Praag and 
de Haan (1980)
44 65 Dep RDC Yes 3 CGI-I > 2 or HRSD > 20 1
Table A1 | Continued
Sample Age Sex 
(%)
Diagnosis Diagnostic 
criteria
Treatment 
resistant 
patients?
Min. no. 
of prior 
episodes
Criteria for defining relapse Stringency
(Continued)
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(1996)
37 57 MDD DSM-III-R Yes 0 (HRSD > 12 for 3 out of 4 weeks) or 
(HRSD > 12 for 1 week + urgent 
need for alternative treatment)
2
Stewart et al. 
(1997)
39 57 Mixed DSM-III Yes 0 CGI-I > 2 for 2 weeks 2
Alexopoulos 
et al. (2000)
73 63 MDD DSM-IV No 0 RDC + DSM-IV + HRSD > 16 3
Georgotas 
et al. (1989)
66 59 MDD RDC No 0 RDC + HRSD > 16 2
Reynolds et al. 
(1999)
68 75 MDD SADS No 2 RDC + confirmed by senior 
psychiatrist
2
Davidson and 
Raft (1984)
NR 88 UPD Feighner No 0 Clinical judgment or patient request 
or HRSD > 20
1
Georgotas 
et al. (1989)
64 50 MDD RDC No 0 RDC + HRSD > 16 2
Harrison et al. 
(1986)
NR 83 MDD DSM-III Yes 0 CGI-I > 2 for 2 weeks 2
Robinson et al. 
(1991)
43 81 MDD DSM-III No 1 (Depressive syndrome + confirmed 
by second therapist) for 2 weeks
4
Stewart et al. 
(1997)
39 57 Mixed DSM-III Yes 0 CGI-I > 2 for 2 weeks 2
Amsterdam 
and Bodkin 
(2006)
43 69 MDD DSM-IV No 0 (HRSD > 13 + CGI-S > 2 + CGI score 
must have increased 2 points from 
baseline score + DSM-IV) for 
2 weeks
8
Table A1 | Continued
Sample Age Sex 
(%)
Diagnosis Diagnostic 
criteria
Treatment 
resistant 
patients?
Min. no. 
of prior 
episodes
Criteria for defining relapse Stringency
(Continued)
Study ADM Class Treatment 
duration 
(months)
Dropout 
rate
Risk period 
(months)
No. 
relapse
N Relapse 
rate
SE
Anton et al. 
(1994)
Placebo PBO 1.63 0.6979 12.00 22 71 0.3099 0.0549
Bremner and 
Smith (1996)
Placebo PBO 1.40 NR 4.67 6 26 0.2308 0.0826
Claghorn and 
Feighner (1993)
Placebo PBO 1.40 0.8083 12.00 8 46 0.1739 0.0559
Detke et al. 
(2004)
Placebo PBO 1.87 0.3763 6.07 17 58 0.2931 0.0598
Entsuah et al. 
(1996)
Placebo PBO 1.40 NR 12.00 26 119 0.2185 0.0379
Montgomery 
et al. (1993)
Placebo PBO 6.00 0.5925 5.60 16 60 0.2667 0.0571
Montgomery 
et al. (1998)
Placebo PBO 1.40 0.7047 4.67 13 57 0.2281 0.0556
Hochstrasser 
et al. (2001)
Citalopram SSRI 5.48 0.3817 11.20 62 132 0.4697 0.0434
Klysner et al. 
(2002)
Citalopram SSRI 5.60 0.4739 11.20 41 61 0.6721 0.0601
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et al. (1993)
Citalopram SSRI 1.40 0.5925 5.60 14 42 0.3333 0.0727
Robert and 
Montgomery 
(1995)
Citalopram SSRI 1.87 0.4220 5.60 20 74 0.2703 0.0516
Gorwood et al. 
(2007)
Escitalopram SSRI 2.80 0.2469 5.60 50 153 0.3268 0.0379
Terra and 
Montgomery 
(1998)
Fluvoxamine SSRI 5.60 0.5321 12.00 32 94 0.3404 0.0489
Emslie et al. 
(2008)
Fluoxetine SSRI 2.80 0.3964 5.60 36 52 0.6923 0.0640
Gilaberte et al. 
(2001)
Fluoxetine SSRI 7 .47 0.4466 11.20 28 70 0.4000 0.0586
McGrath et al. 
(2006)
Fluoxetine SSRI 2.80 0.5404 12.13 94 131 0.7176 0.0393
Montgomery 
et al. (1988)
Fluoxetine SSRI 5.60 0.5175 12.00 54 94 0.5745 0.0510
Reimherr et al. 
(1998)
Fluoxetine SSRI 2.80 0.5292 2.80 46 95 0.4842 0.0513
Schmidt et al. 
(2000)
Fluoxetine SSRI 3.03 0.4624 5.83 61 122 0.5000 0.0453
Dobson et al. 
(2008)
Paroxetine SSRI 3.73 0.5100 12.00 12 21 0.5714 0.1080
Montgomery 
and Dunbar 
(1993)
Paroxetine SSRI 1.87 0.2151 12.00 29 67 0.4328 0.0605
Cheung et al. 
(2008)
Sertraline SSRI 2.80 0.7634 5.60 6 9 0.6667 0.1571
Doogan and 
Caillard (1992)
Sertraline SSRI 1.87 0.6039 12.00 48 110 0.4364 0.0473
Kamijima et al. 
(2006)
Sertraline SSRI 1.87 0.3490 3.73 23 118 0.1949 0.0365
Keller et al. 
(1998)
Sertraline SSRI 6.80 0.6221 17 .73 19 84 0.2262 0.0456
Lustman et al. 
(2006)
Sertraline SSRI 3.73 0.5670 12.13 38 73 0.5205 0.0585
Wilson et al. 
(2003)
Sertraline SSRI 6.07 0.5551 23.33 30 57 0.5263 0.0661
Perahia et al. 
(2006)
Duloxetine SNRI 2.80 0.4784 6.07 59 142 0.4155 0.0414
Perahia et al. 
(2009)
Duloxetine SNRI 7 .93 0.4397 24.00 47 142 0.3310 0.0395
Rickels et al. 
(2010)
Desvenlafaxine SNRI 2.80 0.3687 5.60 90 185 0.4865 0.0367
Table A1 | Continued
(Continued)
Study ADM Class Treatment 
duration 
(months)
Dropout 
rate
Risk period 
(months)
No. 
relapse
N Relapse 
rate
SE
Andrews et al.  Blue again
www.frontiersin.org  July 2011  | Volume 2  |  Article 159  |  23Table A1 | Continued
Rouillon et al. 
(2000)
Milnacipran SNRI 6.00 0.5720 12.00 26 110 0.2364 0.0405
Kocsis et al. 
(2007)
Venlafaxine SNRI 8.33 0.5698 12.00 54 129 0.4186 0.0434
Montgomery 
et al. (2004)
Venlafaxine SNRI 6.00 0.5253 12.00 64 116 0.5517 0.0462
Simon et al. 
(2004)
Venlafaxine SNRI 1.87 0.3510 5.63 64 138 0.4638 0.0425
Coppen et al. 
(1978)
Amitriptyline TCA 2.33 NR 10.00 5 16 0.3125 0.1159
Klerman et al. 
(1974)
Amitriptyline TCA 1.17 0.4604 8.00 7 25 0.2800 0.0898
Stein et al. (1980) Amitriptyline TCA 1.87 0.5565 6.00 16 23 0.6957 0.0959
van Praag and de 
Haan (1980)
Clomipramine TCA 4.43 NR 12.00 8 10 0.8000 0.1265
Kocsis et al. 
(1996)
Desipramine TCA 6.53 0.4884 24.00 12 25 0.4800 0.0999
Stewart et al. 
(1997)
Imipramine TCA 8.87 NR 6.00 7 15 0.4667 0.1288
Alexopoulos 
et al. (2000)
Nortriptyline TCA 3.73 0.5700 24.00 11 21 0.5238 0.1090
Georgotas et al. 
(1989)
Nortriptyline TCA 5.83 NR 12.00 7 14 0.5000 0.1336
Reynolds et al. 
(1999)
Nortriptyline TCA 6.93 0.3369 36.00 26 29 0.8966 0.0566
Davidson and 
Raft (1984)
Phenelzine MAOI 1.75 NR 5.00 8 8 1.0000 0.0764
Georgotas et al. 
(1989)
Phenelzine MAOI 5.83 NR 12.00 8 9 0.8889 0.1048
Harrison et al. 
(1986)
Phenelzine MAOI 4.69 NR 6.00 7 7 1.0000 0.0856
Robinson et al. 
(1991)
Phenelzine MAOI 5.04 0.4659 24.00 13 16 0.8125 0.0976
Stewart et al. 
(1997)
Phenelzine MAOI 7 .47 NR 6.00 13 15 0.8667 0.0878
Amsterdam and 
Bodkin (2006)
Selegiline MAOI 2.33 0.5230 12.00 50 163 0.3067 0.0361
BDI, Beck Depression Inventory; CDRS-R, Children’s Depression Rating Scale-Revised; CGI-I, Clinical Global Impression-Improvement scale; CGI-S, Clinical Global 
Impression-Severity scale; Dep, primary depressive illness; DSM, Diagnostic and Statistical Manual of Mental Disorders; HRSD, Hamilton Research Scale for 
Depression; MADRS, Montgomery–Asberg Depression Research Scale; MRC, Medical Research Council criteria; NR, not reported; RDC, Research Diagnostic 
Criteria; SADS, Schedule for Affective Disorders and Schizophrenia for Children; UPD, unipolar depression.
Study ADM Class Treatment 
duration 
(months)
Dropout 
rate
Risk period 
(months)
No. 
relapse
N Relapse 
rate
SE
Andrews et al.  Blue again
Frontiers in Psychology | Evolutionary Psychology    July 2011  | Volume 2  |  Article 159  |  24